Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 3/20 | 0.83 |
| ▸ | MMP9 | P14780 | 3/20 | 0.83 |
| ▸ | MMP2 | P08253 | 3/20 | 0.83 |
| ▸ | MMP8 | P22894 | 2/20 | 0.83 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.78 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.78 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.78 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.78 |
| ▸ | STAT3 | P40763 | 2/20 | 0.78 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.78 |
| ▸ | RELA | Q04206 | 2/20 | 0.78 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.78 |
| ▸ | MMP13 | P45452 | 2/20 | 0.72 |
| ▸ | APP | P05067 | 4/20 | 0.66 |
| ▸ | MAOB | P27338 | 3/20 | 0.66 |
| ▸ | MAPT | P10636 | 3/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.66 |
| ▸ | TSHR | P16473 | 2/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17014665 | 0.94 | NFKB1 (0.74) | NFKB1MMP9MMP2MMP8CYP2D6 | |
| SCHEMBL4544307 | 0.91 | MMP2 (0.74) | NFKB1MMP9MMP2MMP8CYP2D6 | |
| SCHEMBL11928819 | 0.91 | MMP2 (0.74) | NFKB1MMP9MMP2MMP8CYP2D6 | |
| SCHEMBL13446382 | 0.91 | MMP2 (0.74) | NFKB1MMP9MMP2MMP8CYP2D6 | |
| SCHEMBL15581510 | 0.91 | NFKB1 (0.72) | NFKB1MMP9MMP2MMP8CYP2D6 | |
| SCHEMBL10077702 | 0.91 | MMP9 (1.00) | NFKB1MMP9MMP2MMP8CYP2D6 | |
| SCHEMBL12565705 | 0.91 | MMP9 (1.00) | NFKB1MMP9MMP2MMP8CYP2D6 | |
| SCHEMBL13125782 | 0.91 | MMP9 (1.00) | NFKB1MMP9MMP2MMP8CYP2D6 | |
| SCHEMBL16203057 | 0.91 | MMP9 (1.00) | NFKB1MMP9MMP2MMP8CYP2D6 | |
| SCHEMBL15171945 | 0.89 | MMP9 (0.77) | NFKB1MMP9MMP2MMP8CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180078535-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | IONS PHARMACEUTICAL S.À R.L. (LU) | 2018-03-22 | — | — | US | disclosed |
| US-9907786-B2 | Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof | IONS PHARMACEUTICAL S.À R.L. (LU) | 2018-03-06 | — | — | US | disclosed |
| US-20170216222-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | IONS PHARMACEUTICAL S.À R.L. (LU) | 2017-08-03 | — | — | US | disclosed |
| US-20170105976-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | Ions Pharmaceutical S.à r.I. (LU) | 2017-04-20 | — | — | US | disclosed |
| US-20170105975-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | IONS PHARMACEUTICAL S.À R.L. (LU) | 2017-04-20 | — | — | US | disclosed |
| US-20170042865-A1 | THERAPEUTIC COMPOSITIONS CONTAINING CURCUMIN, HARMINE, AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | IONS PHARMACEUTICAL S.À R.L. (LU) | 2017-02-16 | — | — | US | disclosed |
| US-20170042867-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | IONS PHARMACEUTICAL S.À R.L. (LU) | 2017-02-16 | — | — | US | disclosed |
| US-20170042866-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | IONS PHARMACEUTICAL S.À R.L. (LU) | 2017-02-16 | — | — | US | disclosed |
| US-9402834-B2 | Human therapeutic agents | IONS PHARMACEUTICAL S.À R.L. (LU) | 2016-08-02 | — | — | US | disclosed |
| US-20160106724-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2016-04-21 | — | — | US | disclosed |
| US-9254249-B2 | Ultraviolet absorber | KAO CORPORATION (JP) | 2016-02-09 | — | — | US | disclosed |
| US-20160009623-A1 | Lipophilic Curcumin Analogs And Methods Of Inhibiting HIV-1, Treating Latent HIV In The Brain, And Preventing HIV-Mediated Cognitive Decline And HIV Dementia | HOWARD UNIVERSITY | 2016-01-14 | — | — | US | disclosed |
| US-9187397-B2 | Therapeutic curcumin derivatives | STC.UNM (US) | 2015-11-17 | — | — | US | disclosed |
| US-9012490-B2 | Lipophilic curcumin analogs and methods of inhibiting HIV-1, treating latent HIV in the brain, and preventing HIV-mediated cognitive decline and HIV dementia | HOWARD UNIVERSITY (US) | 2015-04-21 | — | — | US | disclosed |
| US-20150011494-A1 | THERAPEUTIC CURCUMIN DERIVATIVES | STC.UNM | 2015-01-08 | — | — | US | disclosed |
| US-20140079653-A1 | ULTRAVIOLET ABSORBER | KAO CORPORATION (JP) | 2014-03-20 | — | — | US | disclosed |
| US-20140051742-A1 | Lipophilic Curcumin Analogs And Methods Of Inhibiting HIV-1, Treating Latent HIV In The Brain, And Preventing HIV-Mediated Cognitive Decline And HIV Dementia | HOWARD UNIVERSITY | 2014-02-20 | — | — | US | disclosed |
| US-7709535-B2 | Curcumin analogues and uses thereof | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2010-05-04 | — | — | US | disclosed |
| US-20080146660-A1 | NOVEL CURCUMIN ANALOGUES AND USES THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2008-06-19 | — | — | US | disclosed |
| US-7355081-B2 | androgen receptor antagonists; certain cancers, baldness, hirsutism, behavioral disorders, acne, and inhibition of spermatogenesis if so desired | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2008-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146660-A1 | NOVEL CURCUMIN ANALOGUES AND USES THEREOF | AR, NR5A1, BRDT | NFKB1 1410/4885MMP9 2476/4885MMP2 2144/4885 |
| US-20170216222-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | INMT, HNMT, COMT | NFKB1 1602/4885MMP9 2837/4885MMP2 1432/4885 |
| US-20180078535-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | INMT, HNMT, COMT | NFKB1 1602/4885MMP9 2837/4885MMP2 1432/4885 |
| US-20170042865-A1 | THERAPEUTIC COMPOSITIONS CONTAINING CURCUMIN, HARMINE, AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | INMT, HNMT, CPT1A | NFKB1 1171/4885MMP9 1554/4885MMP2 586/4885 |
| US-20170105976-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | INMT, HNMT, COMT | NFKB1 1602/4885MMP9 2837/4885MMP2 1432/4885 |
| US-20140079653-A1 | ULTRAVIOLET ABSORBER | ERCC1, UNG, ERCC4 | NFKB1 1766/4885MMP9 2212/4885MMP2 2691/4885 |
| US-20160009623-A1 | Lipophilic Curcumin Analogs And Methods Of Inhibiting HIV-1, Treating Latent HIV In The Brain, And Preventing HIV-Mediated Cognitive Decline And HIV Dementia | BACE1, GAA, GLA | NFKB1 365/4885MMP9 93/4885MMP2 27/4885 |
| US-20170042867-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | INMT, HNMT, COMT | NFKB1 1602/4885MMP9 2837/4885MMP2 1432/4885 |
| US-20170042866-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | INMT, HNMT, COMT | NFKB1 1602/4885MMP9 2837/4885MMP2 1432/4885 |
| US-20150011494-A1 | THERAPEUTIC CURCUMIN DERIVATIVES | FABP2, GLS2, FABP1 | NFKB1 418/4885MMP9 1372/4885MMP2 399/4885 |
| US-20170105975-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | INMT, HNMT, COMT | NFKB1 1602/4885MMP9 2837/4885MMP2 1432/4885 |
| US-20160106724-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | NFKB1 841/4885MMP9 3366/4885MMP2 899/4885 |
| US-20140051742-A1 | Lipophilic Curcumin Analogs And Methods Of Inhibiting HIV-1, Treating Latent HIV In The Brain, And Preventing HIV-Mediated Cognitive Decline And HIV Dementia | BACE1, GAA, GLA | NFKB1 365/4885MMP9 93/4885MMP2 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.